Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Operating Income

Operating Income at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$8.59M+1.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$75.61M+10.6%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$46.34M+131%
Cytokinetics logo
CytokineticsCYTK
-$179.17M-60.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$110.55M+13.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Research and development40,89918,75368,37438,078
Selling, general and administrative63,86646,863125,01790,393
Total operating expenses216,406136,637401,405261,150
Income from operations27,19420,16056,46133,432
Other income, net3,9512,7177,3655,010
Income before income taxes31,14522,87763,82638,442
Provision for income taxes(5,713)(5,045)(15,802)(12,071)
Net income$25,432$17,832$48,024$26,371

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's operating income?
Kiniksa Pharmaceuticals International, plc (KNSA) reported operating income of $27.19M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's operating income changed year-over-year?
Kiniksa Pharmaceuticals International, plc's operating income increased by 34.9% year-over-year, from $20.16M to $27.19M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's operating income?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's operating income has grown at a -16.2% compound annual growth rate (CAGR), from -$156.64M to $77.22M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Kiniksa Pharmaceuticals International, plc's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude